|
|
11726 San Vicente Blvd., Suite 650
Los Angeles, CA 90049 USA
phone:(310) 826-5648
fax:310-826-6139
|
|
| Symbol |
CYTR |
| Exchange |
NASDAQ |
| Founded |
1985 |
| Employees |
18 |
|
|
| www.cytrx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biopharmaceutical research and development company engaged in the development of human therapeutics. |
|
| Management |
| Steven A. Kriegsman, President and Chief Executive Officer; Daniel Levitt, M.D., Ph.D., Chief Medical Officer; John Y. Caloz, Chief Financial Officer; Jaisim Shah, Senior Business Officer and Senior Vice President of Business Development; Benjamin S. Levin, General Counsel, Vice President of Legal Affairs and Corporate Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| tamibarotene, bafetinib, arimoclomol, iroxanadine, proteins, RNAi, cancer, |
|
|
|
|
|
|
| Description |
|
CytRx is a biopharmaceutical research and development company engaged in the development of human therapeutics. |
|
| Products / Services |
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes tamibarotene which is in a registration study for the treatment of acute promyelocytic leukemia (APL). CytRx�s other oncology programs are bafetinib, a phase 2 ready dual Bcr-Abl and Lyn kinase inhibitor for the treatment of imatinib-resistant CML and other B-cell malignancies, and INNO-206, a novel prodrug of doxorubicin which has improved tumor targeting leading to reduced toxicity. In addition to its cancer programs, CytRx is developing two drug candidates, arimoclomol and iroxanadine, based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease.
CytRx spun-out its RNAi therapeutics subsidiary RXi Pharmaceuticals, Inc. which commenced trading on Nasdaq in March 2008 under the symbol RXII. CytRx maintains a 36% equity interest in RXi.
|
|
| Technology / Differentiation |
| CytRx has several proprietary anti-cancer drug candidates in development. INNO-206 incorporates a unique acid-sensitive linker technology that allows for improved targeting to the tumor. This results in the ability to administer greater amounts of drug and an improved side effect profile. In addition, the Company has two clinical stage drugs based on its molecular chaperone amplification technology. |
|
| Market / Customers |
CytRx is developing drugs for various forms of cancer. Tamibarotene and bafetinib are being developed to treat different types of leukemias. INNO-206 has a linker technology for the treatment of solid tumors including gastric cancers and soft tissue sarcomas.
|
|
| Competitors / Substitutes / Alternatives |
Celgene Corporation, Cephalon, Sanofi-Aventis
|
|
| Status |
| CytRx�s lead compound Tamibarotene is in a pivotal phase 2 clinical trial with a Special Protocol Assessment with the FDA. The trial targets 3rd line APL. A phase 1/2 clinical trial with Tamibarotene in combination with Cephalon�s Trisenox in APL was started in September 2009. The Company recently announced plans for phase 2 clinical trials with INNO-206 in advanced gastric cancer and soft tissue sarcoma. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
